News

Vertex Pharmaceuticals has awarded a $50,000 grant to Claire’s Place Foundation to support its Work Proudly Program, which helps adults with cystic fibrosis (CF) and caregivers with work-from-home opportunities. “We are extremely grateful for the influx of support for our new Work Proudly Program,” Melissa Yeager,…

BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test potential treatments, including one for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). According to a press release, the company expects results of a proof-of-concept…

The European Commission has approved the combination of Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor) for the treatment of children, ages 6 to 11, with cystic fibrosis (CF) carrying certain genetic mutations. Eligible children must carry either two copies of the F508del mutation — the most common mutation…

Music composed especially for children with cystic fibrosis (CF) made airway clearance therapy a more enjoyable task, suggesting that it can help with treatment adherence and potentially lower costs related to pulmonary exacerbations, a study suggests. The study, “Effects of music therapy as an adjunct to…

The Cystic Fibrosis Foundation (CFF) awarded up to $3.75 million to Matinas BioPharma to support preclinical studies of MAT2501, a potential oral antibiotic to treat nontuberculous mycobacterium (NTM) infections in people with cystic fibrosis (CF) and other lung diseases. A goal of this early research work is…

Using pig lungs as a model, scientists discovered that Staphylococcus aureus, a species of bacteria often found in the lungs of children with cystic fibrosis (CF), preferentially colonizes the mucus circulating there rather than organ tissue itself. According to the researchers, these findings may open new ways of treating…

AzurRx BioPharma is requesting a new patient arm be added to its ongoing Phase 2b trial investigating MS1819 capsules as a treatment for exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF). The request, filed with the U.S. Food and Drug Administration (FDA), would add a patient group…